Stock Ratings / Health Care / MIRA / forecast

IMMP (60) SHPH (46) ATOS (36) CRVO (29) ⌘ Pro Terminal →

MIRA Pharmaceuticals Inc. (MIRA) 12-Month Stock Forecast & Price Target Cone

$0.57 +2.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

MIRA Pharmaceuticals Inc. (MIRA) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $24.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MIRA)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your MIRA Position Size: $10,000

Shares at $0.57: 17543.9 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.42

$7,368

$-2,632 (-26.3%)

12M Consensus BaseTarget $0.54

$9,474

$-526 (-5.3%)

12M Bull Case BreakoutTarget $1.84

$32,281

+$22,281 (+222.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$2	69%	B
JP MorganUS Large-Cap Research	SELL	$0	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MIRA)

✓Walkthrough of MIRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MIRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -45.71%▼ DESCENDING CHANNEL

2026-10-30O $0.59H $0.59L $0.51C $0.57VOL 207.9K

RES: $1.04SUP: $0.22SMA50: $0.74SMA200: $0.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MIRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MIRA Butterfly Map → + Track MIRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MIRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MIRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MIRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MIRA)

Health Care Rank #390 of 1016 ⚔️ IMMP vs MIRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MIRA vs. IMMP, SHPH, ATOS, CRVO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MIRA Pharmaceuticals Inc. (MIRA) ranks #390 by composite RQD confidence (48/100, grade D) and #823 by equity capitalization ($24.0M). Within this direct 5-issuer industry benchmark cohort, MIRA leads on earnings valuation at N/A trailing P/E, while MIRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMMP currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with MIRA at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MIRA ACTIVE MIRA Pharmaceuticals Inc.	D	48/100	—	—	-35.0%	+2.79%	$24.0M	Benchmark Subject
IMMP Immutep Limited	C-	60/100	—	—	—	+0.30%	$24.5M	/immp-vs-mira →
SHPH Shuttle Pharmaceuticals Holdings Inc.	D	46/100	—	—	-35.0%	-0.19%	$24.9M	/shph-vs-mira →
ATOS Atossa Therapeutics Inc.	D-	36/100	—	—	-35.0%	-5.91%	$22.3M	/atos-vs-mira →
CRVO CervoMed Inc.	E	29/100	—	—	-35.0%	-20.81%	$26.5M	/crvo-vs-mira →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001904286

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MIRA Pharmaceuticals Inc. (MIRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.4M, operating cash flow of -$4.7M, and free cash flow of -$4.7M (+16.2% YoY). On the balance sheet, MIRA closed FY2025 with $11.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$10.4M	-$4.7M	-$4.7M	$11.1M	—
FY2024 (FY)	2024-12-31	$0	-$7.9M	-$5.6M	-$5.6M	$2.9M	—
FY2023 (FY)	2023-12-31	$0	-$12.0M	-$4.5M	-$4.5M	—	—

3. MIRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MIRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $0.57 (+2.79% 1D, market cap $24.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MIRA ranks #390 in composite RQD confidence.

How does MIRA compare to IMMP and SHPH in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIRA carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMMP (Immutep Limited) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $24.5M) and SHPH (Shuttle Pharmaceuticals Holdings Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $24.9M). Among the 5-stock peer group, MIRA leads on earnings multiple (N/A) while MIRA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MIRA?

Per MIRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001904286), MIRA Pharmaceuticals Inc. generated $0 in revenue, -$10.4M in net income, and -$4.7M in free cash flow against $11.1M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MIRA trading relative to its 50-day, 200-day, and 52-week technical levels?

MIRA last traded at $0.57 (+2.79% on volume of 381,969 shares), positioning the stock -22.97% below its 50-day simple moving average ($0.74) and -40.63% below its 200-day simple moving average ($0.96). Across its 52-week range of $0.51 to $1.75, MIRA sits at the 4.8% percentile with a 14-day RSI of 34.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.64).

MIRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is MIRA's 12-month stock price target?

MIRA Pharmaceuticals Inc. (MIRA) carries a 12-month consensus base price target of $0.54 (-5.3% from $0.57), with a bull-case target of $1.84 and a bear-case floor of $0.42.